by DMCBiotech | Jan 31, 2022 | DMC Press Releases
31 January 2022 – DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. DMC previously...
by DMCBiotech | Dec 2, 2021 | DMC Press Releases, News
2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay...
by DMCBiotech | May 13, 2021 | DMC Press Releases, News
13 May 2021 – DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech in Leuna, Germany following the successful demonstration of commercial scale fermentation at the...
by DMCBiotech | Apr 7, 2021 | DMC Press Releases, News
7 April 2021 – DMC Biotechnologies has executed an agreement with SCG Chemicals Co., Ltd to bring DMC’s L-Alanine and branched chain amino acids (BCAAs) into the ASEAN* markets. SCG was an investor in DMC’s Series A round in December 2019. Matt Lipscomb, Ph.D., CEO...
by DMCBiotech | Mar 24, 2021 | DMC Press Releases, News
24 March 2021 – DMC Co-Founder Mike Lynch has launched a web-based calculator to assess the economic feasibility of products made from fermentation. The Bioprocess Technoeconomic Analysis (TEA) tool will help users – academics, startups, funding agencies, R&D...
by DMCBiotech | Mar 18, 2021 | DMC Press Releases, News
15 March 2021 – DMC Biotechnologies has successfully demonstrated full commercial scale (85m3 fermentation at EW Biotech, Germany) for its first product, the amino acid L-alanine. The scale-up results identically tracked the performance at bench and pilot scales,...
